Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy

  • Technology appraisal guidance
  • TA530
  • Published: 

Review decision - August 2023

Decision to move the existing TA530 guidance to the static list

We would like to update you on the decision made regarding the review of the existing NICE technology appraisal guidance TA530 on nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy.

There is no new evidence that would lead to a change in the existing recommendations. TA530 will move to the static list.

Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

Review decision paper

This page was last updated: